Developments Helus announces positive results from study of deuterated psilocin in MDD Helus Pharma (NASDAQ: HELP; Cboe CA: HELP) has announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major... November 16, 2026